Alzamend Neuro Inc (ALZN) vs Liminatus Pharma, Inc. Class A Common Stock (LIMN)

A side-by-side comparison of Alzamend Neuro Inc and Liminatus Pharma, Inc. Class A Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Alzamend Neuro Inc logo
ALZN
Alzamend Neuro Inc
$5M
$1.39HealthcareDelayed quote: Oct 6, 2026, 1:28 PM EDT
Liminatus Pharma, Inc. Class A Common Stock logo
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$5M
$3.80HealthcareDelayed quote: Oct 6, 2026, 1:28 PM EDT

Total return — ALZN vs LIMN

growth of $100 · dividends reinvested · last 1y
ALZN -77.0% (-77.0%/yr)LIMN -98.4% (-98.4%/yr)ALZN compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $1002026$23$2
ALZN LIMN

ALZN vs LIMN: by the numbers

  • •ALZN is the larger company ($5M vs $5M market cap).

Metrics side by side

Valuation

MetricALZNLIMN
P/B ratio0.9116.98

Profitability

MetricALZNLIMN
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-156.77%-4165.92%
ROIC-156.69%-225.12%

Growth (annualized)

MetricALZNLIMN
Total return CAGR (5Y)-79.14%N/A

Go deeper

Full ALZN analysisFull LIMN analysisInteractive comparison tool

Dig into the metrics

Alzamend Neuro ROELiminatus Pharma, Inc. Class A Common Stock ROEAlzamend Neuro operating marginLiminatus Pharma, Inc. Class A Common Stock operating marginAlzamend Neuro revenue growthLiminatus Pharma, Inc. Class A Common Stock revenue growthAlzamend Neuro free cash flowLiminatus Pharma, Inc. Class A Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.